Rare
lephants
Screener
Toggle theme
Genmab A/S
GMAB
·
Healthcare, Drug Manufacturers - General, Denmark
Financial Statements
Profitability
Balance Sheet
Cash Flow
Price Ratios
Share-Based Metrics
Valuation
Cash Flow History
Net Cash Flow Breakdown
Net Cash Flow
Cash Flow
›
Net Cash Flow Breakdown
Net Cash Flow Breakdown
Chart
Table
FY2025
FY2024
FY2023
Total Cash from Operations:
$5.98B
Line Item
Value
% of Total
Capital Expenditures
$37.0M
0.6%
Other Investing
$5.61B
93.8%
Net Cash Flow
$332.0M
5.6%
Download CSV
